Background: Nonhuman primate (NHP) models of human HIV infection, including the most commonly used model involving SIV-infected Indian rhesus macaques, represent an important component of the HIV cure research agenda. Feasible, sustainable combination antiretroviral treatment (cART) regimens to achieve clinically relevant levels of suppression (SIV plasma RNA < 30 copies/ml) are an essential element to enable use of such models in evaluation of experimental HIV cure strategies, but developing such regimens has proven challenging. Methodology: We compared two different cART regimens (Tenofovir disoproxyl fumarate/Emtricitabine/Dolutegravir; TDF/FTC/DTG vs. Tenofovir disoproxyl fumarate/Emtricitabine/Dolutegravir/Darunavir; TDF/FTC/DTG/DRV), both given as a single, daily, co-formulated subcutaneous injection, in SIVmac239 infected Indian rhesus macaques (n = 3 each), with treatment initiated 2 weeks after intravenous infection. After the initial 4 weeks of treatment, all animals received the TDF/FTC/DTG regimen. We evaluated drug levels, plasma viremia, cell associated SIV RNA and DNA and immune activation. Results: Both regimens were well tolerated based on clinical and laboratory (CBC and serum chemistry panel) evaluations. Starting from pretreatment plasma viral loads of ~3-4 X 10^7 SIV RNA copies/ml, both regimens provided comparable 4 log declines in plasma viremia over the first 4 weeks of treatment, associated with decreased evidence of SIV infection related immune activation, based on HLA-DR and Ki67 expression. Continued treatment of all animals with TDF/FTC/DTG after the initial 4 weeks of cART produced continued declines in plasma viremia, to < 30 copies/ml in all animals, by 22 weeks post-infection (20 weeks on cART). Conclusions: Both regimens resulted in prompt, effective suppression of SIVmac239 replication, as reflected by plasma viremia. There was no clear advantage associated with the addition of Darunavir to the regimen during the initial four weeks of treatment, and with continued treatment with TDF/FTC/DTG all animals were suppressed to < 30 copies/ml. TDF/FTC/DTG is an effective suppressive regimen in SIV-infected Indian rhesus macaques, and should facilitate NHP model studies of interventions targeting residual virus in cART suppressed individuals. TDF/FTC/DTG activity was comparable to that of the same regimen using Tenofovir (TFV) instead of TDF evaluated in prior studies; use of TDF instead of TFV in the combination should help minimize potential renal toxicities with long term administration.